{
  "docId": "019de075-e64c-773b-a5bd-08e51f7033a7",
  "docSlug": "8122e3ca3ef658190e4851ff70e19f61",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 25 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 25,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a timeline-based process diagram to illustrate the clinical trial randomization and treatment arms.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e64c-773b-a5bd-08e51f7033a7/18",
  "deckHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7",
  "deckJsonHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7.json",
  "deckAnchorHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.53,
        "w": 0.66,
        "x": 0.31,
        "y": 0.08
      },
      "kind": "diagram",
      "text": "Clinical trial timeline showing randomization at week 24, treatment arms, and follow-up periods.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8829c114-22a1-46d6-a7f3-dd64e4ece5aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.31,
        "y": 0.72
      },
      "kind": "list",
      "text": "Mean HBsAg decline 1.6 log10 at week 24; 93% of patients had HBsAg <100 IU/mL; 4 patients reached <LLOQ.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05cfc20a-7daf-487c-8ec5-a7c6c365efd0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.31,
        "y": 0.56
      },
      "kind": "paragraph",
      "text": "Multi-center, open-label Phase 2a. Primary objective: evaluate safety and tolerability. Preliminary results: treatment well tolerated, HBsAg declines observed.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae4554b3-7a9c-4954-a247-eaa55cc9a1f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.25,
        "x": 0.04,
        "y": 0.53
      },
      "kind": "paragraph",
      "text": "Imdusiran in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in cHBV patients",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9d1014f-029c-44fe-ade4-a3a523b0410e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.22,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "title",
      "text": "AB-729-201: Phase 2a POC Clinical Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "148c9fe4-858b-48a7-8b11-0180c388be2b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Three-Act Structure",
      "slug": "three-act-structure",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "cbb8917a-ad72-4ac9-a2fc-749ac96f7c34",
      "evidence": "The slide presents a clinical trial with a clear setup (Phase 2a POC Clinical Trial), confrontation (evaluation of safety and tolerability), and resolution (preliminary results showing treatment well tolerated and HBsAg declines observed).",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "ea8c6d59-dc65-4693-9ad9-c92dd51afde5",
      "evidence": "Visual representation of clinical trial phases over time.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}